TP53 and myelodysplastic syndrome: We examined risk-associated markers in complex karyotype MDS such as the presence of MK, specific chromosomal lesions, total number of lesions, clinical variables, and the presence of TP53 mutations to determine which features had independent prognostic value that could be used to better risk stratify patients with complex karyotype MDS.